Detailed price information for Prime Medicine Inc (PRME-Q) from The Globe and Mail including charting and trades.
Prime Medicine, Inc. maintains a Buy rating, supported by an advancing prime editing pipeline and multiple upcoming clinical catalysts. Click for a PRME update.
The FDA clears Prime Medicine’s IND application for PM647, an investigational in vivo Prime Editor for AATD, for human trials.
Gainers Prime Medicine (NASDAQ:PRME) shares increased by 13.0% to $3.47 during Thursday's after-market session. The market value of their outstanding shares is at $567.7 million. Onconetix (NASDAQ:ONCO) stock rose
CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in three upcoming conferences: Wells Fargo 21st Annual Healthcare Conference: Company management will host 1x1 meetings on Thursday, September 10, 2026, in Boston, MA.H.C. Wainwright 28th Annual Global Investment Conference: Fireside chat
This is the newest page. Registered accounts read further back.